John T Poirier, Julie George, Taofeek K Owonikoko, Anton Berns, Elisabeth Brambilla, Lauren A Byers, David Carbone, Huanhuan J Chen, Camilla L Christensen, Caroline Dive, Anna F Farago, Ramaswamy Govindan, Christine Hann, Matthew D Hellmann, Leora Horn, Jane E Johnson, Young S Ju, Sumin Kang, Mark Krasnow, James Lee, Se-Hoon Lee, Jonathan Lehman, Benjamin Lok, Christine Lovly, David MacPherson, David McFadden, John Minna, Matthew Oser, Keunchil Park, Kwon-Sik Park, Yves Pommier, Vito Quaranta, Neal Ready, Julien Sage, Giorgio Scagliotti, Martin L Sos, Kate D Sutherland, William D Travis, Christopher R Vakoc, Sarah J Wait, Ignacio Wistuba, Kwok Kin Wong, Hua Zhang, Jillian Daigneault, Jacinta Wiens, Charles M Rudin, Trudy G Oliver
The outcomes of patients with SCLC have not yet been substantially impacted by the revolution in precision oncology, primarily owing to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunotherapy are beginning to show promise in the clinic. Although, these results are encouraging, many patients do not respond to, or rapidly recur after, current regimens, necessitating alternative or complementary therapeutic strategies. In this review, we discuss ongoing investigations into the pathobiology of this recalcitrant cancer and the therapeutic vulnerabilities that are exposed by the disease state...
April 2020: Journal of Thoracic Oncology